Switch theme
Sign up to access all valuation multiples
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
2015
107
LTM Revenue $84.1M
LTM EBITDA -$37.2M
$149M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Y-mAbs Therapeutics has a last 12-month revenue (LTM) of $84.1M and a last 12-month EBITDA of -$37.2M.
In the most recent fiscal year, Y-mAbs Therapeutics achieved revenue of $87.7M and an EBITDA of -$30.7M.
Y-mAbs Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Y-mAbs Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $84.1M | XXX | $87.7M | XXX | XXX | XXX |
| Gross Profit | $70.4M | XXX | $72.4M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | -$37.2M | XXX | -$30.7M | XXX | XXX | XXX |
| EBITDA Margin | -44% | XXX | -35% | XXX | XXX | XXX |
| EBIT | -$37.5M | XXX | -$31.2M | XXX | XXX | XXX |
| EBIT Margin | -45% | XXX | -36% | XXX | XXX | XXX |
| Net Profit | -$35.9M | XXX | -$29.7M | XXX | XXX | XXX |
| Net Margin | -43% | XXX | -34% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Y-mAbs Therapeutics's stock price is $5.
Y-mAbs Therapeutics has current market cap of $209M, and EV of $149M.
See Y-mAbs Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $149M | $209M | XXX | XXX | XXX | XXX | $-0.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Y-mAbs Therapeutics has market cap of $209M and EV of $149M.
Y-mAbs Therapeutics's trades at 1.7x EV/Revenue multiple, and -4.9x EV/EBITDA.
Equity research analysts estimate Y-mAbs Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Y-mAbs Therapeutics has a P/E ratio of -5.8x.
See valuation multiples for Y-mAbs Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $209M | XXX | $209M | XXX | XXX | XXX |
| EV (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | -4.9x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -4.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.8x | XXX | -7.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialY-mAbs Therapeutics's last 12 month revenue growth is 4%
Y-mAbs Therapeutics's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.0M for the same period.
Y-mAbs Therapeutics's rule of 40 is -25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Y-mAbs Therapeutics's rule of X is -34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Y-mAbs Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | -44% | XXX | -35% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -25% | XXX | -31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Y-mAbs Therapeutics acquired XXX companies to date.
Last acquisition by Y-mAbs Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Y-mAbs Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Y-mAbs Therapeutics founded? | Y-mAbs Therapeutics was founded in 2015. |
| Where is Y-mAbs Therapeutics headquartered? | Y-mAbs Therapeutics is headquartered in United States of America. |
| How many employees does Y-mAbs Therapeutics have? | As of today, Y-mAbs Therapeutics has 107 employees. |
| Who is the CEO of Y-mAbs Therapeutics? | Y-mAbs Therapeutics's CEO is Mr. Michael Rossi. |
| Is Y-mAbs Therapeutics publicy listed? | Yes, Y-mAbs Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Y-mAbs Therapeutics? | Y-mAbs Therapeutics trades under YMAB ticker. |
| When did Y-mAbs Therapeutics go public? | Y-mAbs Therapeutics went public in 2018. |
| Who are competitors of Y-mAbs Therapeutics? | Similar companies to Y-mAbs Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Y-mAbs Therapeutics? | Y-mAbs Therapeutics's current market cap is $209M |
| What is the current revenue of Y-mAbs Therapeutics? | Y-mAbs Therapeutics's last 12 months revenue is $84.1M. |
| What is the current revenue growth of Y-mAbs Therapeutics? | Y-mAbs Therapeutics revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Y-mAbs Therapeutics? | Current revenue multiple of Y-mAbs Therapeutics is 1.8x. |
| Is Y-mAbs Therapeutics profitable? | Yes, Y-mAbs Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Y-mAbs Therapeutics? | Y-mAbs Therapeutics's last 12 months EBITDA is -$37.2M. |
| What is Y-mAbs Therapeutics's EBITDA margin? | Y-mAbs Therapeutics's last 12 months EBITDA margin is -44%. |
| What is the current EV/EBITDA multiple of Y-mAbs Therapeutics? | Current EBITDA multiple of Y-mAbs Therapeutics is -4.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
